bioRxiv · 10.1101/287888
Appraising the causal relevance of DNA methylation for risk of lung cancer
Abstract
DNA methylation changes in peripheral blood have been identified in relation to lung cancer risk. However, the causal nature of these associations remains to be fully elucidated. Meta-analysis of four epigenome-wide association studies (918 cases, 918 controls) revealed differential methylation at 16 CpG sites (FDR < 0.05) in relation to lung cancer risk. A two-sample Mendelian randomization analysis, using genetic instruments for methylation at 14 of the 16 CpG sites, and 29,863 cases and 55,586 controls from the TRICL-ILCCO lung cancer consortium, was performed to appraise the causal role of methylation at these sites on lung cancer. This approach provided little evidence that DNA methylation in peripheral blood at the 14 CpG sites play a causal role in lung cancer development, including for cg05575921 AHRR, where methylation is strongly associated with lung cancer risk. Further studies are needed to investigate the causal role played by DNA methylation in lung tissue.
Source connections
Explore related subjects
Keep this discovery
Battram, T., Richmond, R., Baglietto, L., Haycock, P., Perduca, V., Bojesen, S., Gaunt, T., Hemani, G., Guida, F., Carreras Torres, R., Hung, R., Amos, C., Freeman, J., Sandanger, T., Nost, T. H., Nordestgaard, B., Teschendorff, A., Polidoro, S., Vineis, P., Severi, G., Hodge, A., Giles, G., Grankvist, K., Johansson, M., Davey Smith, G., Relton, C.. 2018-03-26. Appraising the causal relevance of DNA methylation for risk of lung cancer. https://doi.org/10.1101/287888
Cite the original work for its findings. Save a collection to share your selection of sources.